Optimizing Antitachycardia Pacing in Subcutaneous ICDs

Subcutaneous implantable cardioverter-defibrillators (S-ICDs) have changed the balance between protection from sudden cardiac death and the complications associated with transvenous leads. By placing the shocking coil and sensing electrodes beneath the skin rather than inside the heart, they avoid many bloodstream and lead-related problems. Their principal limitation is equally important: conventional S-ICDs do not provide antitachycardia pacing (ATP).

That distinction matters when clinicians discuss programming, ventricular tachycardia (VT) management and device outcomes. ATP can terminate some monomorphic VT without a painful high-voltage shock, while an S-ICD generally treats detected VT with a shock. An accurate strategy therefore requires clinicians to separate established S-ICD programming from emerging extravascular systems that may offer pacing therapies.

For Australian electrophysiology teams, the question is practical as well as technical. Patient selection, screening, access to device clinics and the distance between a regional patient and a metropolitan service all influence the real-world value of an implantable defibrillator. Programming must reduce avoidable shocks without compromising rapid treatment of life-threatening arrhythmia.

Clarifying What The System Can Deliver

The current conventional S-ICD uses a subcutaneous lead and pulse generator to sense rhythm and deliver defibrillation. It has no intracardiac ventricular lead and cannot pace the ventricle for ATP. Some models provide brief post-shock pacing, generally intended to support bradycardia after a shock, but this is different from programmed ATP for organised VT.

Consequently, an S-ICD cannot be “optimised” for ATP in the same way as a transvenous ICD. The relevant optimisation targets are sensing accuracy, detection zones, therapy delays, shock energy, conditional discrimination and the prevention of inappropriate therapy. Device choice should be based on the patient’s need for pacing, anticipated ATP benefit and risk of venous lead complications.

Emerging extravascular ICD platforms are changing this discussion. A substernal system can place a therapy electrode closer to the heart and may support ATP, pause prevention and defibrillation without a conventional intravascular lead. Availability, regulatory status and clinical experience vary, so these systems should not be treated as interchangeable with established S-ICDs in guidelines or routine consent discussions.

Why ATP Matters Clinically

ATP delivers a sequence of paced impulses faster than the detected tachycardia, aiming to interrupt re-entry and restore sinus rhythm. It is particularly useful for stable monomorphic VT, where a painless pacing burst may terminate the episode. Successful ATP can reduce shocks, preserve battery longevity and improve the patient’s experience of living with an ICD.

ATP is not universally effective. Faster VT, polymorphic VT and ventricular fibrillation usually require defibrillation, and an unsuccessful pacing attempt can delay shock delivery if detection and safety intervals are poorly configured. The clinical benefit depends on the arrhythmia substrate, cycle length, ventricular function, medication profile and the device’s ability to distinguish VT from supraventricular tachycardia.

In patients who need frequent ATP, a transvenous ICD or an ATP-capable extravascular device may be more appropriate than a conventional S-ICD. Conversely, a patient with no pacing indication, limited venous access or a high risk of infection may still gain considerable benefit from an S-ICD, even though shocks remain its main ventricular tachycardia therapy.

Programming Principles For ATP-Capable Devices

Where ATP is available, programming should reflect the patient’s documented VT rather than relying on a generic sequence. A clinician may select burst or ramp pacing, determine the number of pulses, set the coupling interval as a percentage of the tachycardia cycle length and provide more than one attempt before shock therapy. These decisions should be guided by stored electrograms, prior therapy response and the characteristics of the clinical VT.

Longer detection intervals and carefully selected therapy zones can allow self-terminating or slower arrhythmias to settle before treatment. This approach must be balanced against the risk of haemodynamic deterioration. A patient with rapid clinical decline may require a more assertive strategy, while a stable patient with recurrent, well-tolerated monomorphic VT may benefit from additional ATP attempts.

For an S-ICD, equivalent programming attention shifts towards conditional zones and shock timing. The conditional zone uses morphology and other discriminators to identify supraventricular rhythms, while the shock zone provides treatment for very fast rates. The precise settings depend on the manufacturer, model and patient, and should be checked against current programming recommendations rather than copied from a transvenous ICD.

Detection And Discrimination

Inappropriate shocks may result from atrial fibrillation with a rapid ventricular response, sinus tachycardia, T-wave oversensing, myopotentials, lead movement or signal artefact. S-ICD screening before implantation helps identify suitable sensing vectors, but changing body habitus, exercise, posture and lead integrity can alter signal quality over time.

Programming is therefore inseparable from follow-up. Stored episodes should be reviewed with surface electrocardiography, intracardiac or subcutaneous electrograms where available, symptom timing and activity history. A shock delivered for an incorrectly classified rhythm is a clinical event requiring investigation, not merely a programming nuisance.

The experience of advanced discrimination is relevant across ICD platforms. A report on inappropriate shock reduction illustrates why rhythm classification, sensing quality and therapy algorithms should be assessed together. Although the exact tools differ between transvenous and subcutaneous systems, the outcome goal is shared: deliver necessary therapy promptly and avoid unnecessary shocks.

Measuring Outcomes Beyond Shock Counts

The most visible endpoint is the number of shocks, but it is not sufficient. Studies should distinguish appropriate shocks, inappropriate shocks, ATP attempts, successful ATP, failed ATP followed by shock, syncope, hospitalisation and arrhythmic death. A low shock rate may reflect effective ATP, an under-treated patient or a population with little arrhythmia exposure.

Patient-reported outcomes deserve equal attention. Anxiety about shocks, restrictions on driving, sleep disturbance and confidence in physical activity can shape quality of life even when the device functions normally. Remote monitoring can identify recurrent episodes early, but its value depends on reliable connectivity, an agreed review pathway and timely communication with the patient.

Battery longevity and procedural burden are also important. Repeated shocks consume more energy than ATP, while generator replacement carries infection and surgical risks. For an S-ICD, the absence of ATP may increase the number of shocks in selected patients with recurrent monomorphic VT; that potential disadvantage should be weighed prospectively during shared decision-making.

Australian Practice Considerations

Australian care includes major metropolitan electrophysiology services in Sydney, Melbourne, Brisbane and Perth, alongside patients living in regional and remote areas. A person from the Northern Territory or far north Queensland may face flights, accommodation costs and delayed in-person review. Remote monitoring and clear escalation plans can be especially valuable, although internet access and local clinical support are not uniform.

The regulatory and funding environment also matters. Device availability depends on Therapeutic Goods Administration approval, hospital procurement and local expertise, while reimbursement and follow-up arrangements may differ between public hospitals and private practice. Clinicians should explain whether a newer ATP-capable extravascular system is routinely available in Australia or remains limited to selected centres or research pathways.

Australian lifestyle and language should be considered during counselling. A patient who works FIFO, farms outside regional towns or plays contact sport may have practical concerns about travel, wound protection and device position. Advice needs to be specific and plain-spoken—“what happens if it fires?” is often more useful than a lengthy explanation of therapy counters—while still covering emergency care and driving rules.

Research Priorities And Future Systems

Prospective research should compare conventional S-ICDs, transvenous ICDs and ATP-capable extravascular systems in clinically relevant groups. Important subgroups include patients with hypertrophic cardiomyopathy, inherited arrhythmia syndromes, non-ischaemic cardiomyopathy, recurrent monomorphic VT and limited venous access. Outcomes should include shocks, ATP success, complications, quality of life and total healthcare use.

Programming studies should also examine whether individualised therapy based on prior electrograms improves outcomes. Machine learning may assist rhythm discrimination, but algorithms require validation across different body sizes, ethnic groups, exercise patterns and sensing configurations. Australian registries could add valuable evidence from geographically dispersed populations and mixed public-private care pathways.

The central issue is not whether ATP is theoretically attractive. It is whether a specific patient needs pacing therapy, whether the selected device can deliver it reliably and whether programming reduces harm without delaying defibrillation. For conventional S-ICDs, optimisation means making shock-based therapy as selective and safe as possible. For emerging extravascular systems, it means proving that ATP can add benefit without recreating the complications these devices were designed to avoid.

Researchers and clinicians can follow new device evidence, guideline updates and electrophysiology education through the journal’s themed collections. Teams developing Australian studies, clinical reports or technical reviews can also use the journal’s submission contact to identify the appropriate editorial pathway. Careful device selection and transparent programming discussions will remain essential as subcutaneous and extravascular defibrillation continue to develop.